Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGENASDAQ:CNTANASDAQ:SANANASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$40.64+2.0%$36.65$26.20▼$63.50$1.82B1.7523,047 shs432,456 shsCNTACentessa Pharmaceuticals$12.59+2.6%$13.56$7.75▼$19.09$1.64B1.53627,370 shs509,183 shsSANASana Biotechnology$1.71-3.9%$1.87$1.26▼$9.49$401.35M1.753.33 million shs2.84 million shsSDGRSchrödinger$23.36-2.3%$22.85$16.60▼$28.47$1.71B1.84842,996 shs1.48 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics+1.98%+7.48%+23.71%+11.22%-23.75%CNTACentessa Pharmaceuticals+2.61%+1.21%+5.44%-26.24%+43.23%SANASana Biotechnology-3.93%-5.79%+0.59%-45.89%-81.55%SDGRSchrödinger-2.34%-2.09%-8.71%-6.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPGEApogee Therapeutics2.1471 of 5 stars3.50.00.00.02.84.20.0CNTACentessa Pharmaceuticals3.6236 of 5 stars4.51.00.00.04.03.30.6SANASana Biotechnology2.2316 of 5 stars3.40.00.00.02.93.30.6SDGRSchrödinger2.2758 of 5 stars3.51.00.00.02.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 3.00Buy$94.60132.78% UpsideCNTACentessa Pharmaceuticals 3.00Buy$27.00114.46% UpsideSANASana Biotechnology 2.86Moderate Buy$10.80531.58% UpsideSDGRSchrödinger 3.00Buy$32.8040.41% UpsideCurrent Analyst Ratings BreakdownLatest SANA, APGE, SDGR, and CNTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025CNTACentessa PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Outperform$6.005/8/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.004/24/2025SANASana BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.004/16/2025SDGRSchrödingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.003/31/2025CNTACentessa PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$38.003/26/2025CNTACentessa PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/18/2025SANASana BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/18/2025SANASana BiotechnologyCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$5.003/14/2025SANASana BiotechnologyJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$7.003/13/2025APGEApogee TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$95.003/11/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.00(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$7.50 per shareN/ACNTACentessa Pharmaceuticals$6.85M245.44N/AN/A$2.42 per share5.20SANASana BiotechnologyN/AN/AN/AN/A$1.46 per shareN/ASDGRSchrödinger$230.49M7.40$0.62 per share37.42$7.60 per share3.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$83.99M-$3.29N/AN/AN/AN/A-21.81%-20.94%N/ACNTACentessa Pharmaceuticals-$151.09M-$1.81N/AN/AN/AN/A-52.13%-38.01%N/ASANASana Biotechnology-$283.26M-$0.88N/AN/AN/AN/A-84.22%-44.97%N/ASDGRSchrödinger$40.72M-$2.63N/AN/AN/A-91.84%-35.77%-24.51%7/30/2025 (Estimated)Latest SANA, APGE, SDGR, and CNTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025APGEApogee Therapeutics-$1.19-$0.95+$0.24-$0.95N/AN/A5/12/2025Q1 2025CNTACentessa Pharmaceuticals-$0.35-$0.20+$0.15-$0.20N/AN/A5/8/2025Q1 2025SANASana Biotechnology-$0.22-$0.20+$0.02-$0.21N/AN/A5/7/2025Q1 2025SDGRSchrödinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million3/24/2025Q4 2024CNTACentessa Pharmaceuticals-$0.38-$0.34+$0.04-$0.84N/AN/A3/17/2025Q4 2024SANASana Biotechnology-$0.25-$0.23+$0.02-$0.21N/AN/A3/3/2025Q4 2024APGEApogee Therapeutics-$0.94-$1.19-$0.25-$1.19N/AN/A2/26/2025Q4 2024SDGRSchrödinger-$0.35-$0.55-$0.20-$0.55$83.20 million$88.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ASDGRSchrödingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A16.3916.39CNTACentessa Pharmaceuticals0.1521.5221.52SANASana BiotechnologyN/A4.474.47SDGRSchrödingerN/A4.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%CNTACentessa Pharmaceuticals82.01%SANASana Biotechnology88.23%SDGRSchrödinger79.05%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics36.10%CNTACentessa Pharmaceuticals7.09%SANASana Biotechnology30.10%SDGRSchrödinger8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9144.88 million28.77 millionOptionableCNTACentessa Pharmaceuticals200133.60 million116.56 millionOptionableSANASana Biotechnology380225.48 million153.83 millionOptionableSDGRSchrödinger79073.04 million66.59 millionOptionableSANA, APGE, SDGR, and CNTA HeadlinesRecent News About These CompaniesSchrödinger, Inc. (NASDAQ:SDGR) Given Average Rating of "Buy" by AnalystsMay 16 at 2:23 AM | americanbankingnews.comLazard Asset Management LLC Acquires 58,541 Shares of Schrödinger, Inc. (NASDAQ:SDGR)May 15 at 6:29 AM | marketbeat.comSchrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant LymphomaMay 14 at 9:30 AM | businesswire.comCentiva Capital LP Invests $353,000 in Schrödinger, Inc. (NASDAQ:SDGR)May 14 at 4:39 AM | marketbeat.comSchonfeld Strategic Advisors LLC Trims Holdings in Schrödinger, Inc. (NASDAQ:SDGR)May 13 at 4:25 AM | marketbeat.comQ2 EPS Estimates for Schrödinger Cut by Leerink PartnrsMay 13 at 1:31 AM | marketbeat.comBrevan Howard Capital Management LP Makes New Investment in Schrödinger, Inc. (NASDAQ:SDGR)May 12, 2025 | marketbeat.comAlgert Global LLC Sells 34,870 Shares of Schrödinger, Inc. (NASDAQ:SDGR)May 12, 2025 | marketbeat.com16,866 Shares in Schrödinger, Inc. (NASDAQ:SDGR) Acquired by Raymond James Financial Inc.May 12, 2025 | marketbeat.comSchrödinger (NASDAQ:SDGR) Releases Earnings Results, Misses Expectations By $0.01 EPSMay 11, 2025 | marketbeat.comDimensional Fund Advisors LP Has $15.55 Million Stake in Schrödinger, Inc. (NASDAQ:SDGR)May 11, 2025 | marketbeat.comSchrödinger, Inc. (SDGR) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comSchrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2025 | zacks.comSchrödinger, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 7, 2025 | seekingalpha.comSchrödinger Reports Strong First Quarter 2025 Financial ResultsMay 7, 2025 | businesswire.comAquatic Capital Management LLC Sells 23,673 Shares of Schrödinger, Inc. (NASDAQ:SDGR)May 6, 2025 | marketbeat.comSchrödinger to Present at BofA Securities 2025 Healthcare ConferenceMay 5, 2025 | finance.yahoo.comMarshall Wace LLP Sells 44,639 Shares of Schrödinger, Inc. (NASDAQ:SDGR)May 5, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Makes New Investment in Schrödinger, Inc. (NASDAQ:SDGR)May 4, 2025 | marketbeat.comWells Fargo & Company MN Reduces Stake in Schrödinger, Inc. (NASDAQ:SDGR)May 4, 2025 | marketbeat.comSchrödinger (SDGR) Expected to Announce Earnings on WednesdayMay 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSANA, APGE, SDGR, and CNTA Company DescriptionsApogee Therapeutics NASDAQ:APGE$40.64 +0.79 (+1.98%) As of 05/15/2025 04:00 PM EasternApogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Centessa Pharmaceuticals NASDAQ:CNTA$12.59 +0.32 (+2.61%) As of 05/15/2025 04:00 PM EasternCentessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Sana Biotechnology NASDAQ:SANA$1.71 -0.07 (-3.93%) As of 05/15/2025 04:00 PM EasternSana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Schrödinger NASDAQ:SDGR$23.36 -0.56 (-2.34%) As of 05/15/2025 04:00 PM EasternSchrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? AMD’s AI-Powered Stock Price Rally Just Shifted Gears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
